Business Wire

O2 (Telefónica UK) Chooses MDS Global to Enhance Direct Partner Capabilities with New Insight Portal

2.10.2019 11:00:00 EEST | Business Wire | Press release

Share

MDS Global Ltd, a leading BSS-as-a-Service provider and O2 (Telefónica UK), have developed and implemented a new Partner Insight Portal – providing O2’s Direct Partners with focused customer and business intelligence. The data-rich portal aims to improve customer service and facilitate bespoke billing and information for sales acquisition.

The O2 Direct Partner Network is made up of a small number of providers from across the UK, chosen by O2 to work with business customers of all sizes on the company’s behalf and to help deliver brilliant digital experiences to business end users.

Until recently, Direct Partners could only view billing information by requesting it through O2’s call centre. The web-based MDS Global system makes integrated analytics instantly accessible, through a secure, and easy-to-use web portal. It can be used by business partner call centre operatives and their sales teams to check the status of service, requests, complaints, sales, and billing. The more accurate real-time data, (which answers questions such as how services are being used, identifies areas of profit and loss, and profiles customers for better sales targeting) will improve call handling, and customer satisfaction scores.

Equally important, the Portal enables information sharing with partners, whilst ensuring customer confidentiality at all times. O2 can securely configure the Partner Insight Portal so that the stored data can be filtered and tailored for a specific business partner, keeping irrelevant or private customer information hidden and adhering to GDPR rules.

Jason Phillips, Head of Partner Sales at O2, said, "At O2, we have a customer-first, mobile-led approach. While we have the highest expectations of our partners in delivering world-class customer experience, it is up to us to make sure they have the information they need to do this. Our new Insight Portal, supplied by MDS Global, is designed to have a positive impact on customer retention. It provides us and our partners with more comprehensive customer and business information so we can offer the highest levels of service, every time."

Chris Ruddle, Finance Director at Welcomm – an O2 Direct Partner – said: “I am delighted that Welcomm was amongst the first partners to have access to O2’s new Partner Insight Portal. It will not only improve the efficiency of our customer care team in dealing with customer queries, but will also provide us with up-to-date information we need to take our customer support to the next level.”

John Roulston, Sales Director at Barclays, adds: “O2’s Insight Portal launch is something we have been excited about for some time. From sales to service, it will change every aspect of how we drive experience for our customers. Churn, service delivery and revenue will all benefit from this excellent innovation and investment from O2. I’m certain this will be the main catalyst for growth over the next few years. We look forward to embracing it long term.”

Gary Bunney, CEO at MDS Global, said: "The Portal will transform the customer and business partner experience. We expect it to decrease churn through improved customer visibility and to help direct partners manage profitability."

About Telefónica UK(O2)

O2 is a mobile network operator and the principal commercial brand of Telefónica UK Limited, which is part of the global telecommunications group Telefónica S.A, headquartered in Spain and operating in Europe, and North, Central and South America.

Telefónica UK Limited is registered in England and Wales. Registration number: 1743099.

About MDS Global

MDS Global, based in the UK, is a leading BSS-as-a-Service provider of VNO, B2B and IoT solutions.

www.mdsglobal.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Martine Naughton
martine.naughton@mdsglobal.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye